BriaPro six-month net loss rises to $472,231; going concern doubt noted
BriaCell Therapeutics filed interim financial statements for its subsidiary BriaPro Therapeutics for the three and six months ended January 31, 2026, showing larger losses than a year earlier and a shareholders' deficit of $1,618,141. The filing states there is a material uncertainty about BriaPro's ability to continue as a going concern, and that it depends entirely on BriaCell for funding until it raises additional financing.
Key points
- Six-month net loss was $472,231, compared with $233,185 in the prior-year period; three-month net loss was $227,493, compared with $151,062.
- Six-month research and development expenses were $433,307, compared with $130,023 a year earlier.
- Amounts due to related parties were $1,606,112 at January 31, 2026, and cash and cash equivalents were $1.
- On February 18, 2026, BriaPro agreed to acquire BriaCell's license to Soluble CD80; the transaction closed March 30, 2026, with 23,972,589 shares issued to BriaCell and a credit facility of up to $3,000,000.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.